Skip to main content
PMC home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 2005 Mar;42(3):247–252. doi: 10.1136/jmg.2004.025791

Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey)

B Hoffmann 1, d Garcia 1, A Mehta 1, M Beck 1, U Widmer 1, R Ricci 1, b on 1
PMCID: PMC1736022  PMID: 15744039

Abstract

Background: Fabry disease is an X linked lysosomal storage disease caused by deficiency of the lysosomal enzyme α-galactosidase A. This leads to accumulation of globotriaosylceramide in nearly all tissues, including the blood vessels, kidney, myocardium, and nervous system. Symptoms often begin in childhood and include acroparaesthesia, with burning or tingling pain that spreads from the extremities to more proximal sites.

Aims: This study set out to evaluate pain and its influence on quality of life in patients with Fabry disease receiving enzyme replacement therapy (ERT) with agalsidase alfa.

Methods: Data were obtained from the Fabry Outcome Survey. Pain was measured using the Brief Pain Inventory (BPI), and health-related quality of life (HRQoL) was documented with the European Quality of Life Questionnaire (EQ-5D).

Results: The mean (SD) score for "pain at its worst" on the BPI prior to ERT was 5.1 (2.7). One year after commencement of ERT, this had improved by 0.5, and improved by a further 0.6 after 2 years (p<0.05). Similar statistically significant improvements were seen for "pain on average" and "pain now" after 2 years of ERT. The mean HRQoL utility score prior to ERT was 0.66 (0.32). After 12 months of treatment with agalsidase alfa, this had improved to 0.74 (0.26; p<0.05); this improvement was maintained after 2 years.

Conclusions: ERT with agalsidase alfa significantly reduces pain and improves quality of life in patients with Fabry disease.

Full Text

The Full Text of this article is available as a PDF (91.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baehner F., Kampmann C., Whybra C., Miebach E., Wiethoff C. M., Beck M. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis. 2003;26(7):617–627. doi: 10.1023/b:boli.0000005658.14563.77. [DOI] [PubMed] [Google Scholar]
  2. Beer G., Reinecke P., Gabbert H. E., Hort W., Kuhn H. Fabry disease in patients with hypertrophic cardiomyopathy (HCM). Z Kardiol. 2002 Dec;91(12):992–1002. doi: 10.1007/s00392-002-0870-7. [DOI] [PubMed] [Google Scholar]
  3. Bergner M. Quality of life, health status, and clinical research. Med Care. 1989 Mar;27(3 Suppl):S148–S156. doi: 10.1097/00005650-198903001-00012. [DOI] [PubMed] [Google Scholar]
  4. Brady R. O., Schiffmann R. Clinical features of and recent advances in therapy for Fabry disease. JAMA. 2000 Dec 6;284(21):2771–2775. doi: 10.1001/jama.284.21.2771. [DOI] [PubMed] [Google Scholar]
  5. Branton Mary H., Schiffmann Raphael, Sabnis Sharda G., Murray Gary J., Quirk Jane M., Altarescu Gheona, Goldfarb Lev, Brady Roscoe O., Balow James E., Austin Iii Howard A. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002 Mar;81(2):122–138. doi: 10.1097/00005792-200203000-00003. [DOI] [PubMed] [Google Scholar]
  6. Breitbart W., Rosenfeld B., Passik S., Kaim M., Funesti-Esch J., Stein K. A comparison of pain report and adequacy of analgesic therapy in ambulatory AIDS patients with and without a history of substance abuse. Pain. 1997 Aug;72(1-2):235–243. doi: 10.1016/s0304-3959(97)00039-0. [DOI] [PubMed] [Google Scholar]
  7. Brooks R. Quality of life measures. Crit Care Med. 1996 Oct;24(10):1769–1769. doi: 10.1097/00003246-199610000-00027. [DOI] [PubMed] [Google Scholar]
  8. Bryan S., Ratcliffe J., Neuberger J. M., Burroughs A. K., Gunson B. K., Buxton M. J. Health-related quality of life following liver transplantation. Qual Life Res. 1998 Feb;7(2):115–120. doi: 10.1023/a:1008849224815. [DOI] [PubMed] [Google Scholar]
  9. Cleeland C. S. Pain assessment: the advantages of using pain scales in lysosomal storage diseases. Acta Paediatr Suppl. 2002;91(439):43–47. doi: 10.1111/j.1651-2227.2002.tb03109.x. [DOI] [PubMed] [Google Scholar]
  10. Cleeland C. S., Ryan K. M. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994 Mar;23(2):129–138. [PubMed] [Google Scholar]
  11. Cleemput Irina, Kesteloot Katrien, De Geest Sabina, Dobbels Fabienne, Vanrenterghem Yves. Health professionals' perceptions of health status after renal transplantation: a comparison with transplantation candidates' expectations. Transplantation. 2003 Jul 15;76(1):176–182. doi: 10.1097/01.TP.0000072807.46212.FA. [DOI] [PubMed] [Google Scholar]
  12. Conner-Spady B., Cumming C., Nabholtz J. M., Jacobs P., Stewart D. Responsiveness of the EuroQol in breast cancer patients undergoing high dose chemotherapy. Qual Life Res. 2001;10(6):479–486. doi: 10.1023/a:1013018218360. [DOI] [PubMed] [Google Scholar]
  13. Davison Sara N. Pain in hemodialysis patients: prevalence, cause, severity, and management. Am J Kidney Dis. 2003 Dec;42(6):1239–1247. doi: 10.1053/j.ajkd.2003.08.025. [DOI] [PubMed] [Google Scholar]
  14. Dütsch M., Marthol H., Stemper B., Brys M., Haendl T., Hilz M. J. Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol. 2002 Dec;19(6):575–586. doi: 10.1097/00004691-200212000-00011. [DOI] [PubMed] [Google Scholar]
  15. Gallagher Rollin M. Low back pain, health status, and quality of life in older adults: challenge and opportunity. Pain Med. 2003 Dec;4(4):305–307. doi: 10.1111/j.1526-4637.2003.03049.x. [DOI] [PubMed] [Google Scholar]
  16. Gold K. F., Pastores G. M., Botteman M. F., Yeh J. M., Sweeney S., Aliski W., Pashos C. L. Quality of life of patients with Fabry disease. Qual Life Res. 2002 Jun;11(4):317–327. doi: 10.1023/a:1015511908710. [DOI] [PubMed] [Google Scholar]
  17. Grünfeld J. P., Lidove O., Joly D., Barbey F. Renal disease in Fabry patients. J Inherit Metab Dis. 2001;24 (Suppl 2):71–65. doi: 10.1023/a:1012475908718. [DOI] [PubMed] [Google Scholar]
  18. Hennessy C. H., Moriarty D. G., Zack M. M., Scherr P. A., Brackbill R. Measuring health-related quality of life for public health surveillance. Public Health Rep. 1994 Sep-Oct;109(5):665–672. [PMC free article] [PubMed] [Google Scholar]
  19. Kampmann Christoph, Baehner Frank, Ries Markus, Beck Michael. Cardiac involvement in Anderson-Fabry disease. J Am Soc Nephrol. 2002 Jun;13 (Suppl 2):S147–S149. [PubMed] [Google Scholar]
  20. Kampmann Christoph, Wiethoff Christiane M., Perrot A., Beck Michael, Dietz Rainer, Osterziel Karl J. The heart in Anderson Fabry disease. Z Kardiol. 2002 Oct;91(10):786–795. doi: 10.1007/s00392-002-0848-5. [DOI] [PubMed] [Google Scholar]
  21. LYON M. F. Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature. 1961 Apr 22;190:372–373. doi: 10.1038/190372a0. [DOI] [PubMed] [Google Scholar]
  22. Linhart A., Magage S., Palecek T., Bultas J. Cardiac involvement in Fabry disease. Acta Paediatr Suppl. 2002;91(439):15–20. doi: 10.1111/j.1651-2227.2002.tb03104.x. [DOI] [PubMed] [Google Scholar]
  23. Lyon M. F. X-chromosome inactivation and human genetic disease. Acta Paediatr Suppl. 2002;91(439):107–112. doi: 10.1111/j.1651-2227.2002.tb03120.x. [DOI] [PubMed] [Google Scholar]
  24. MacDermot K. D., Holmes A., Miners A. H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001 Nov;38(11):750–760. doi: 10.1136/jmg.38.11.750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Macran S., Kind P. "Death" and the valuation of health-related quality of life. Med Care. 2001 Mar;39(3):217–227. doi: 10.1097/00005650-200103000-00003. [DOI] [PubMed] [Google Scholar]
  26. Mehta A., Ricci R., Widmer U., Dehout F., Garcia de Lorenzo A., Kampmann C., Linhart A., Sunder-Plassmann G., Ries M., Beck M. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004 Mar;34(3):236–242. doi: 10.1111/j.1365-2362.2004.01309.x. [DOI] [PubMed] [Google Scholar]
  27. Meikle P. J., Hopwood J. J., Clague A. E., Carey W. F. Prevalence of lysosomal storage disorders. JAMA. 1999 Jan 20;281(3):249–254. doi: 10.1001/jama.281.3.249. [DOI] [PubMed] [Google Scholar]
  28. Miners A. H., Holmes A., Sherr L., Jenkinson C., MacDermot K. D. Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention. Qual Life Res. 2002 Mar;11(2):127–133. doi: 10.1023/a:1015009210639. [DOI] [PubMed] [Google Scholar]
  29. Morrone A., Cavicchi C., Bardelli T., Antuzzi D., Parini R., Di Rocco M., Feriozzi S., Gabrielli O., Barone R., Pistone G. Fabry disease: molecular studies in Italian patients and X inactivation analysis in manifesting carriers. J Med Genet. 2003 Aug;40(8):e103–e103. doi: 10.1136/jmg.40.8.e103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Nicholson Bruce, Verma Sunil. Comorbidities in chronic neuropathic pain. Pain Med. 2004 Mar;5 (Suppl 1):S9–S27. doi: 10.1111/j.1526-4637.2004.04019.x. [DOI] [PubMed] [Google Scholar]
  31. Obrador Gregorio T., Ojo Akinlolu, Thadhani Ravi. End-stage renal disease in patients with Fabry disease. J Am Soc Nephrol. 2002 Jun;13 (Suppl 2):S144–S146. [PubMed] [Google Scholar]
  32. Peters F. P., Vermeulen A., Kho T. L. Anderson-Fabry's disease: alpha-galactosidase deficiency. Lancet. 2001 Jan 13;357(9250):138–140. doi: 10.1016/s0140-6736(00)03554-6. [DOI] [PubMed] [Google Scholar]
  33. Phillips Ceri J. Prise en charge de la douleur: réflexions sur l'économie de la santé et la qualité de vie. Drugs. 2003;63(SPEC):47–50. [PubMed] [Google Scholar]
  34. Ries M., Mengel E., Kutschke G., Kim K. S., Birklein F., Krummenauer F., Beck M. Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. J Inherit Metab Dis. 2003;26(4):413–414. doi: 10.1023/a:1025127723729. [DOI] [PubMed] [Google Scholar]
  35. Rodríguez-Marí Adriana, Coll M. José, Chabás Amparo. Molecular analysis in Fabry disease in Spain: fifteen novel GLA mutations and identification of a homozygous female. Hum Mutat. 2003 Sep;22(3):258–258. doi: 10.1002/humu.9172. [DOI] [PubMed] [Google Scholar]
  36. Santanello Nancy C., Baker Drew, Cappelleri Joseph C., Copley-Merriman Kati, DeMarinis Robert, Gagnon Jean Paul, Hsuan Alice, Jackson Joseph, Mahmoud Ramy, Miller David. Regulatory issues for health-related quality of life--PhRMA Health Outcomes Committee workshop, 1999. Value Health. 2002 Jan-Feb;5(1):14–25. doi: 10.1046/j.1524-4733.2002.51047.x. [DOI] [PubMed] [Google Scholar]
  37. Schiffmann R., Kopp J. B., Austin H. A., 3rd, Sabnis S., Moore D. F., Weibel T., Balow J. E., Brady R. O. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001 Jun 6;285(21):2743–2749. doi: 10.1001/jama.285.21.2743. [DOI] [PubMed] [Google Scholar]
  38. Schiffmann R. Natural history of Fabry disease in males: preliminary observations. J Inherit Metab Dis. 2001;24 (Suppl 2):15–12. doi: 10.1023/a:1012499119196. [DOI] [PubMed] [Google Scholar]
  39. Schiffmann Raphael, Floeter Mary Kay, Dambrosia James M., Gupta Surya, Moore David F., Sharabi Yehonatan, Khurana Ramesh K., Brady Roscoe O. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve. 2003 Dec;28(6):703–710. doi: 10.1002/mus.10497. [DOI] [PubMed] [Google Scholar]
  40. Sculco A. D., Paup D. C., Fernhall B., Sculco M. J. Effects of aerobic exercise on low back pain patients in treatment. Spine J. 2001 Mar-Apr;1(2):95–101. doi: 10.1016/s1529-9430(01)00026-2. [DOI] [PubMed] [Google Scholar]
  41. Tan Gabriel, Jensen Mark P., Thornby John I., Shanti Bilal F. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain. 2004 Mar;5(2):133–137. doi: 10.1016/j.jpain.2003.12.005. [DOI] [PubMed] [Google Scholar]
  42. Trippoli S., Vaiani M., Lucioni C., Messori A. Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. Pharmacoeconomics. 2001;19(8):855–863. doi: 10.2165/00019053-200119080-00007. [DOI] [PubMed] [Google Scholar]
  43. Whybra C., Kampmann C., Willers I., Davies J., Winchester B., Kriegsmann J., Brühl K., Gal A., Bunge S., Beck M. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis. 2001 Dec;24(7):715–724. doi: 10.1023/a:1012993305223. [DOI] [PubMed] [Google Scholar]
  44. Whybra C., Wendrich K., Ries M., Gal A., Beck M. Clinical manifestation in female Fabry disease patients. Contrib Nephrol. 2001;(136):245–250. doi: 10.1159/000060196. [DOI] [PubMed] [Google Scholar]
  45. van Agt H. M., Essink-Bot M. L., Krabbe P. F., Bonsel G. J. Test-retest reliability of health state valuations collected with the EuroQol questionnaire. Soc Sci Med. 1994 Dec;39(11):1537–1544. doi: 10.1016/0277-9536(94)90005-1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES